Merck Won a Wider EU Bladder Cancer Label for Keytruda. Here’s What Its ESMO Data Needs to Show

Key Stats for Merck StockCurrent Price: $149. 88Target Price (Mid): ~$161Street Target: ~$159Potential Total Return: ~8%Annualized IRR: ~2% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?Merck (MRK) won a wider European Union label for Keytruda plus Padcev in muscle-invasive bladder cancer on October 21.